APLS - Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

As of May 22, 2026: spot at $39.17, ATM IV 25.3%, max pain $40.00, net GEX $705.6K.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$5.25B

P/E Ratio

38.80

Beta

-0.25

52-Week Range

16.61-41.14

CEO

Cedric Francois

Employees

705

IPO Date

Nov 9, 2017

Exchange

NASDAQ

What APLS Looks Like to Options Traders Today

IV rank of 4.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($705.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.136) prices calls richer than puts, often reflecting upside speculation or squeeze risk.

What This Page Covers

The APLS overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.